Bracco to establish operations in U.K., Ireland
Pharmaceutical firm Bracco plans to establish imaging operations in the U.K. and Ireland by the end of this year, the Milan-based firm announced this month. The move allows Bracco to take over operations in these two countries currently managed by Merck
Pharmaceutical firm Bracco plans to establish imaging operations in the U.K. and Ireland by the end of this year, the Milan-based firm announced this month. The move allows Bracco to take over operations in these two countries currently managed by Merck Pharmaceuticals Imaging, a division of Merck of Germany. Merck Pharmaceuticals will continue to distribute Braccos contrast media products in the U.K. and Ireland until Braccos operations are in place. Bracco products distributed by Merck include x-ray contrast agents Niopam and Iomeron, as well as MRI agents ProHance and MultiHance.
The agreement is part of Braccos move to acquire Mercks 50% share in its imaging and pharmaceutical businesses, which was announced in January. Pending regulatory approval, Bracco will pay Merck $900 million over five years (SCAN 1/12/00).
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
July 25th 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 2
July 23rd 2025In the second part of a multi-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, discuss key sequences for abbreviated breast MRI and how it stacks up to other breast cancer screening modalities.
Chest CT for Post-COVID-19 Abnormalities: Nine Takeaways from a Multi-Society Consensus Statement
July 22nd 2025Developed by 21 thoracic radiologists, the new international consensus statement addresses appropriate indications, scan acquisition and keys to reporting for the use of chest CT imaging in evaluating for residual lung abnormalities from COVID-19.
